Cargando…

Analysis of Hormone Receptor Status in Primary and Recurrent Breast Cancer Via Data Mining Pathology Reports

BACKGROUND: Hormone receptors of breast cancer, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her-2), are important prognostic factors for breast cancer. OBJECTIVE: The current study aimed to develop a method to retrieve the statistics of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Kai-Po, Chu, Yen-Wei, Wang, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401490/
https://www.ncbi.nlm.nih.gov/pubmed/30847396
http://dx.doi.org/10.1515/med-2019-0013
Descripción
Sumario:BACKGROUND: Hormone receptors of breast cancer, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her-2), are important prognostic factors for breast cancer. OBJECTIVE: The current study aimed to develop a method to retrieve the statistics of hormone receptor expression status, documented in pathology reports, given their importance in research for primary and recurrent breast cancer, and quality management of pathology laboratories. METHOD: A two-stage text mining approach via regular expression-based word/phrase matching, was developed to retrieve the data. RESULTS: The method achieved a sensitivity of 98.8%, 98.7% and 98.4% for extraction of ER, PR, and Her-2 results. The hormone expression status from 3679 primary and 44 recurrent breast cancer cases was successfully retrieved with the method. Statistical analysis of these data showed that the recurrent disease had a significantly lower positivity rate for ER (54.5% vs 76.5%, p=0.001278) than primary breast cancer and a higher positivity rate for Her-2 (48.8% vs 16.2%, p=9.79e-8). These results corroborated the previous literature. CONCLUSION: Text mining on pathology reports using the developed method may benefit research of primary and recurrent breast cancer.